Valley Fever Institute

Help Raise Awareness of AMR

The COVID-19 crisis has reinforced the critical importance of treatments for infectious diseases; however, our supply of e­ffective antibiotics is shrinking due to the growth of antimicrobial resistance (AMR). AMR is a threat to all of us, especially organ transplant recipients, those undergoing cancer treatment or major surgeries like joint replacements, preterm infants, immunocompromised patients and vulnerable patients with other chronic health conditions. According to the Centers for Disease Control and Prevention (CDC), currently, more than 2.8 million drug-resistant infections occur in the U.S. each year and more than 35,000 people die as a result.

Infectious disease cases, including those of Valley Fever, continue to climb at a drastic rate. Valley Fever cases nationally have more than tripled in the last 10 years. Valley Fever symptoms mimic other illnesses, leading to delayed diagnosis and an increased use of antibiotics which contributes to AMR.

Now more than ever the development of new antimicrobial drugs is paramount to help combat diseases like Valley Fever and mitigate the economic costs. An estimated $1.5 Billion is spent annually to treat Valley Fever in California and Arizona alone. Without the development of new drugs these costs will continue to increase with the number of diagnosed cases.

Please join us. We can all find a way to help raise awareness of Antimicrobial Resistance.

  • Raise awareness about the steps that we can all take to help address the threats posed by infectious disease, from patients and physicians to health policy experts, community organizations, business and labor groups.
  • Better educate people at risk, caregivers, healthcare providers, policymakers, and all other stakeholders, on the significant impact and threat of infectious diseases.
  • Advocate for policy changes that will advance solutions to ensure future pandemic preparedness.

Everyone can make a difference – from patients taking their full course of their medicines, to physicians using diagnostics and following clinical prescribing guidelines, to insurers providing access to clinically appropriate medicines without barriers, to policy makers helping to shape an environment that fuels development of new antimicrobial medicines.

ACTION NEEDED: Development of new diagnostics and antifungal treatments to reduce the toll of drug-resistant and fungal infections.

To support the development of new antimicrobial products, policy makers must create strong financial incentives for investing in new treatments paired with policies that address stewardship and surveillance, stabilize the current market through payment and reimbursement reforms, and address barriers that prevent patients from getting access to the appropriate medicines.

The Valley Fever Institute welcomes organizations to lend their voices in raising awareness of threats posed by infectious diseases like Valley Fever as well as advance solutions to ensure future pandemic preparedness.



For Additional Information about AMR, please visit our partners

Antibiotic / Antimicrobial Resistance | CDC

Partnership to Fight Infectious Disease

Translate »